<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113087</url>
  </required_header>
  <id_info>
    <org_study_id>177</org_study_id>
    <secondary_id>U01HL068270</secondary_id>
    <secondary_id>U01HL068279</secondary_id>
    <secondary_id>U01HL068281</secondary_id>
    <secondary_id>U01HL068285</secondary_id>
    <secondary_id>U01HL068288</secondary_id>
    <secondary_id>U01HL068290</secondary_id>
    <secondary_id>U01HL068292</secondary_id>
    <secondary_id>U01HL068269</secondary_id>
    <nct_id>NCT00113087</nct_id>
  </id_info>
  <brief_title>Trial of Angiotensin Converting Enzyme Inhibition in Infants With Single Ventricle--Pediatric Heart Network</brief_title>
  <acronym>ISV</acronym>
  <official_title>Trial of ACE Inhibition in Infants With Single Ventricle (A Trial Conducted by the Pediatric Heart Network)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Heart Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Heart, Lung, and Blood Institute (NHLBI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of administering an angiotensin converting
      enzyme inhibitor (ACE-I) (enalapril) to infants with a functional single ventricle. The study
      will also compare the effect of ACE-I therapy to placebo on somatic growth and compare the
      effect of ACE-I therapy to placebo on signs and symptoms of heart failure, neurodevelopmental
      and functional status, ventricular geometry, function, and atrioventricular (AV) valve
      regurgitation. In addition, the study will determine the relationship between genetic
      polymorphisms linked to ventricular hypertrophy (enlarged heart) and the response to ACE-I
      therapy and compare the incidence of adverse events in subjects treated with ACE-I with those
      in subjects treated with placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Growth impairment is common in infants and children with congenital heart disease, most often
      in the presence of congestive heart failure and/or cyanosis. Growth failure is noted in many
      infants with a single ventricle who manifest both cyanosis and heart failure that commonly
      persist after palliative surgery. Whether this impairment is related to persistent or
      progressive abnormalities in cardiac structure and function is not known. ACE-Is are widely
      used in the treatment of infants with severe congestive heart failure to improve cardiac
      function and somatic growth. The ability of an ACE-I to improve somatic growth in infants
      with a single ventricle has not been previously studied.

      This study has been approved by the Institutional Review Boards/Research Ethics Boards of all
      participating clinical centers:

      Hospital for Sick Children, Toronto, Canada

      Children's Hospital Boston, Boston, MA

      Columbia College of Physicians and Surgeons, New York, NY

      Children's Hospital of Philadelphia, Philadelphia, PA

      Duke University Medical Center, Durham, NC

      Brody School of Medicine at East Carolina University, Greenville, NC

      Wake Forest Baptist Medical Center, Winston Salem, NC

      Medical University of South Carolina, Charleston, SC

      Primary Children's Medical Center, Salt Lake City, UT

      Children's Hospital of Wisconsin, Milwaukee, WI

      Cincinnati Children's Hospital Medical Center, Cincinnati, OH

      DESIGN NARRATIVE:

      This is a prospective, randomized, double-blind, placebo-controlled trial of ACE-I in infants
      with a single ventricle. After stratification by ventricular anatomy, neonates will be
      randomly assigned to receive enalapril or placebo and then followed for 14 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight-for-age Z-score at 14 Months of Age</measure>
    <time_frame>Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age</time_frame>
    <description>Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height-for-age Z-score</measure>
    <time_frame>Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age</time_frame>
    <description>Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Head Circumference-for-age Z-score</measure>
    <time_frame>Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age</time_frame>
    <description>Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ross Heart Failure Class I</measure>
    <time_frame>Just prior to the pre-Glenn surgery</time_frame>
    <description>Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ross Heart Failure Class I</measure>
    <time_frame>Measured at 14 months of age</time_frame>
    <description>Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-Type Natriuretic Peptide</measure>
    <time_frame>Measured just prior to the Glenn surgery</time_frame>
    <description>B-Type Natriuretic Peptide (BNP) level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-type Natriuretic Peptide Level</measure>
    <time_frame>at the time of the 14 month visit</time_frame>
    <description>B-type natriuretic peptide (BNP) level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Neurodevelopmental status (PDI):
the Bayley Scales of Infant Development: Psychomotor Development index z-score .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental Status (FSII)</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MacArthur-Bates Inventory -Phrases Understood</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MacArthur-Bates Inventory -Words Understood</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MacArthur-Bates Inventory -Total Gestures</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MacArthur-Bates Inventory -Words Produced</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Fraction (%)</measure>
    <time_frame>just before the Glenn surgery</time_frame>
    <description>Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Fraction (%)</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Mass</measure>
    <time_frame>just before the Glenn surgery</time_frame>
    <description>Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Mass</measure>
    <time_frame>At 14 months of age</time_frame>
    <description>Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Mass Z-score</measure>
    <time_frame>just before the Glenn surgery</time_frame>
    <description>Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Mass Z-score</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-diastolic Volume</measure>
    <time_frame>just before the Glenn surgery</time_frame>
    <description>Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-diastolic Volume</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End Diastolic Volume Z-score</measure>
    <time_frame>just before the Glenn surgery</time_frame>
    <description>Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End-diastolic Volume Z-score</measure>
    <time_frame>at 14 months of age</time_frame>
    <description>Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Mass to Volume Ratio</measure>
    <time_frame>Measured just before the Glenn surgery</time_frame>
    <description>Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Mass to Volume Ratio</measure>
    <time_frame>Measured at 14 months of age</time_frame>
    <description>Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular Filling Pressure</measure>
    <time_frame>just before the Glenn surgery</time_frame>
    <description>Ventricular filling pressure measured by catherization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate to Severe AV Valve Regurgitation</measure>
    <time_frame>just before the pre-Glenn surgery</time_frame>
    <description>Number of participants with Moderate to severe AV valve regurgitation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Moderate to Severe AV Valve Regurgitation</measure>
    <time_frame>at age 14 months</time_frame>
    <description>Number of participants with moderate to severe AV valve regurgitation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>Enalapril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enalapril (angiotensin converting enzyme inhibitor)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (Ora-Plus and Ora-Sweet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)</description>
    <arm_group_label>Enalapril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Less than or equal to 45 days of age

          -  Age greater than 1 week if born at 35 weeks gestation

          -  Single ventricle physiology

          -  Stable systemic and pulmonary blood flow

          -  Planned Glenn shunt surgery (or variant known as hemi-Fontan)

        Exclusion Criteria:

          -  Birth weight less than or equal to 2.5 kg if gestational age is greater than or equal
             to 38 weeks

          -  Birth weight less than the 10th percentile for gestational age if gestational age is
             35 to 37 weeks

          -  Less than 35 weeks gestation

          -  Anatomic diagnosis of pulmonary atresia with intact ventricular septum

          -  Less than 3 days after palliative cardiac surgical procedure, if performed

          -  Aortic oxygen saturation less than 65%

          -  Current mechanical ventilatory support

          -  Current intravenous inotropic support

          -  Creatinine greater than 1.0 mg/dL

          -  Absolute neutrophil count less than 1,000 cells/mL

          -  Chromosomal or recognizable phenotypic syndrome of noncardiac congenital abnormalities
             associated with growth failure (e.g., Trisomy 21, Noonan's syndrome, Turner's
             syndrome)

          -  Prior ACE inhibitor use for greater than 7 consecutive days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Page Anderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Medical Center, Durham, NC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daphne Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Children's Hospital at Montefiore, NYC, NY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian McCrindle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>LuAnn Minich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Primary Children's Hospital, Salt Lake City, UT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Newburger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Boston, Boston, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Philip Saul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynn Sleeper, Sc.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New England Research Institute, Watertown, MA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Vetter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia, Philadelphia, PA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woodrow Benson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cincinnati Children's Medical Center, Cincinnati, OH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2005</study_first_submitted>
  <study_first_submitted_qc>June 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2005</study_first_posted>
  <results_first_submitted>September 4, 2009</results_first_submitted>
  <results_first_submitted_qc>September 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 16, 2010</results_first_posted>
  <last_update_submitted>September 16, 2010</last_update_submitted>
  <last_update_submitted_qc>September 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Lynn Sleeper, PI</name_title>
    <organization>New England Research Institutes</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Enalapril</title>
          <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo suspension</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death or Transplant</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family or MD withdrew subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Enalapril</title>
          <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo suspension</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="230"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.1" spread="8.9"/>
                    <measurement group_id="B2" value="20.7" spread="9.1"/>
                    <measurement group_id="B3" value="20.4" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight-for-age Z-score at 14 Months of Age</title>
        <description>Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values)</description>
        <time_frame>Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Weight-for-age Z-score at 14 Months of Age</title>
          <description>Weight-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of weight z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values)</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" spread="0.13"/>
                    <measurement group_id="O2" value="-0.42" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Height-for-age Z-score</title>
        <description>Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value)</description>
        <time_frame>Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Height-for-age Z-score</title>
          <description>Height-for-age z-score at 14 months of age. In primary analysis outcome is defined as predicted mean of height z-score at age 14 months based on longitudinal modeling (adjusted bor baseline value)</description>
          <units>standard deviation</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" spread="0.13"/>
                    <measurement group_id="O2" value="-0.86" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Head Circumference-for-age Z-score</title>
        <description>Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values)</description>
        <time_frame>Measured at baseline, 2 weeks after starting study drug, just prior to the Glenn surgery, 7 days after restarting drug following the Glenn surgery, at 10 months of age, and at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Head Circumference-for-age Z-score</title>
          <description>Head circumference-for-age z-score at 14 months of age.In primary analysis outcome is defined as predicted mean of Head circumference z-score at age 14 months based on longitudinal modeling(and adjusted for baseline values)</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.17"/>
                    <measurement group_id="O2" value="0.09" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-0.64</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ross Heart Failure Class I</title>
        <description>Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise.</description>
        <time_frame>Just prior to the pre-Glenn surgery</time_frame>
        <population>Intention-to-treat analysis of participants measured just prior to the Glenn surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ross Heart Failure Class I</title>
          <description>Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise.</description>
          <population>Intention-to-treat analysis of participants measured just prior to the Glenn surgery</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.00</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ross Heart Failure Class I</title>
        <description>Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise.</description>
        <time_frame>Measured at 14 months of age</time_frame>
        <population>Intention-to-treat analysis of participants completing the final study visit (target visit window age 14 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ross Heart Failure Class I</title>
          <description>Class I is defined as having no limitations or symptoms of heart failure. Classes II to IV include increasing degrees of growth failure, prolonged feeding time, tachypnea, diaphoresis, and in older children, dyspnea on exercise.</description>
          <population>Intention-to-treat analysis of participants completing the final study visit (target visit window age 14 months)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.71</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>B-Type Natriuretic Peptide</title>
        <description>B-Type Natriuretic Peptide (BNP) level.</description>
        <time_frame>Measured just prior to the Glenn surgery</time_frame>
        <population>ITT analysis, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>B-Type Natriuretic Peptide</title>
          <description>B-Type Natriuretic Peptide (BNP) level.</description>
          <population>ITT analysis, no imputation</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="30" upper_limit="182"/>
                    <measurement group_id="O2" value="84" lower_limit="36" upper_limit="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.74</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>B-type Natriuretic Peptide Level</title>
        <description>B-type natriuretic peptide (BNP) level.</description>
        <time_frame>at the time of the 14 month visit</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>B-type Natriuretic Peptide Level</title>
          <description>B-type natriuretic peptide (BNP) level.</description>
          <population>ITT, no imputation</population>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="13" upper_limit="35"/>
                    <measurement group_id="O2" value="39" lower_limit="21" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score</title>
        <description>Neurodevelopmental status (PDI):
the Bayley Scales of Infant Development: Psychomotor Development index z-score .</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Neurodevelopmental Status (PDI): the Bayley Scales of Infant Development,Psychomotor Development Index Z-score</title>
          <description>Neurodevelopmental status (PDI):
the Bayley Scales of Infant Development: Psychomotor Development index z-score .</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.29" spread="1.19"/>
                    <measurement group_id="O2" value="-1.32" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score</title>
        <description>Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score .</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, not imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Neurodevelopmental Status(MDI): Bayley Scales of Infant Development, Mental Developmental Index Z-score</title>
          <description>Neurodevelopmental status(MDI):Bayley Scales of infant development, Mental Developmental Index z-score .</description>
          <population>ITT, not imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.91"/>
                    <measurement group_id="O2" value="-0.33" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neurodevelopmental Status (FSII)</title>
        <description>Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Neurodevelopmental Status (FSII)</title>
          <description>Functional status II (Revised) Total Score. Scale ranges up to 100.00, the higher the better. The score presents an instrument for assessing health status for children surviving long term with chronic physcial disorders.</description>
          <population>ITT, no imputation</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4" lower_limit="89" upper_limit="100"/>
                    <measurement group_id="O2" value="96.4" lower_limit="86" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.60</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MacArthur-Bates Inventory -Phrases Understood</title>
        <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>MacArthur-Bates Inventory -Phrases Understood</title>
          <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Phrases Understood z-score.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="1.11"/>
                    <measurement group_id="O2" value="-0.92" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MacArthur-Bates Inventory -Words Understood</title>
        <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>MacArthur-Bates Inventory -Words Understood</title>
          <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Understood z-score.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.46" spread="0.91"/>
                    <measurement group_id="O2" value="-0.82" spread="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MacArthur-Bates Inventory -Total Gestures</title>
        <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>MacArthur-Bates Inventory -Total Gestures</title>
          <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Total Gestures z-score.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="1.07"/>
                    <measurement group_id="O2" value="-1.31" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MacArthur-Bates Inventory -Words Produced</title>
        <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>MacArthur-Bates Inventory -Words Produced</title>
          <description>MacArthur-Bates Communicative Development inventory( Words and Gestures)-Words Produced z-score.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" lower_limit="-0.72" upper_limit="0.41"/>
                    <measurement group_id="O2" value="-0.63" lower_limit="-0.75" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ejection Fraction (%)</title>
        <description>Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume.</description>
        <time_frame>just before the Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ejection Fraction (%)</title>
          <description>Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction % is defined as the percentage of the stroke volume (i.e. difference between end-diastolic and end-systolic volumes) in a ventricle relative to end-diastolic volume.</description>
          <population>ITT, no imputation</population>
          <units>percent (of end diastolic volume)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" spread="9.8"/>
                    <measurement group_id="O2" value="56.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ejection Fraction (%)</title>
        <description>Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ejection Fraction (%)</title>
          <description>Two-dimensional echocardiography endpoint -Total Ejection Fraction (%) per Core Laboratory assessment. Ejection Fraction (%) is defined as percentage of stroke volume of a ventricle (i.e. the difference between end diastolic and end systolic volumes)relative to end diastolic volume.</description>
          <population>ITT, no imputation</population>
          <units>percent (of end diastolic volume)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" spread="9.6"/>
                    <measurement group_id="O2" value="57.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Mass</title>
        <description>Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment.</description>
        <time_frame>just before the Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Mass</title>
          <description>Two-dimensional echocardiography endpoint - Total Ventricular mass (g) per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="9.2"/>
                    <measurement group_id="O2" value="28.1" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Mass</title>
        <description>Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40</description>
        <time_frame>At 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Mass</title>
          <description>Two-Dimensional Echocardiography endpoint-Total Ventricular mass (g) per Core Laboratory assessment. Range from 15.60 to 70.40</description>
          <population>ITT, no imputation</population>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="10.3"/>
                    <measurement group_id="O2" value="34.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Mass Z-score</title>
        <description>Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment.</description>
        <time_frame>just before the Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Mass Z-score</title>
          <description>Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.9"/>
                    <measurement group_id="O2" value="4.9" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Mass Z-score</title>
        <description>Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Mass Z-score</title>
          <description>Two-dimensional echocardiography endpoint -Total Ventricular mass z-score per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.3"/>
                    <measurement group_id="O2" value="3.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-diastolic Volume</title>
        <description>Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment.</description>
        <time_frame>just before the Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>End-diastolic Volume</title>
          <description>Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" spread="10.1"/>
                    <measurement group_id="O2" value="23.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-diastolic Volume</title>
        <description>Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>End-diastolic Volume</title>
          <description>Two-Dimensional Echocardiography endpoint - Total End-diastolic volume (ml) per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.2" spread="10.0"/>
                    <measurement group_id="O2" value="30.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.35</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End Diastolic Volume Z-score</title>
        <description>Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment.</description>
        <time_frame>just before the Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>End Diastolic Volume Z-score</title>
          <description>Two-dimensional echocardiography endpoint -total End diastolic volume z-score per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="2.5"/>
                    <measurement group_id="O2" value="2.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-diastolic Volume Z-score</title>
        <description>Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment.</description>
        <time_frame>at 14 months of age</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>End-diastolic Volume Z-score</title>
          <description>Two-dimensional echocardiography endpoint -total end-diastolic volume z-score per Core Laboratory assessment.</description>
          <population>ITT, no imputation</population>
          <units>standard deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="2.1"/>
                    <measurement group_id="O2" value="1.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Mass to Volume Ratio</title>
        <description>Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment.</description>
        <time_frame>Measured just before the Glenn surgery</time_frame>
        <population>Intention-to-treat analysis of participants completing the pre-Glenn visit</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Mass to Volume Ratio</title>
          <description>Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment.</description>
          <population>Intention-to-treat analysis of participants completing the pre-Glenn visit</population>
          <units>g/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="0.43"/>
                    <measurement group_id="O2" value="1.31" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Mass to Volume Ratio</title>
        <description>Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment.</description>
        <time_frame>Measured at 14 months of age</time_frame>
        <population>Intention-to-treat analysis of participants completing the final study visit (target visit window age 14 months)</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Mass to Volume Ratio</title>
          <description>Two-Dimensional Echocardiography endpoint -Ventricular Mass to Volume ratio per Core Laboratory assessment.</description>
          <population>Intention-to-treat analysis of participants completing the final study visit (target visit window age 14 months)</population>
          <units>g/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.38"/>
                    <measurement group_id="O2" value="1.20" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventricular Filling Pressure</title>
        <description>Ventricular filling pressure measured by catherization</description>
        <time_frame>just before the Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular Filling Pressure</title>
          <description>Ventricular filling pressure measured by catherization</description>
          <population>ITT, no imputation</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9" spread="3.6"/>
                    <measurement group_id="O2" value="11.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.81</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate to Severe AV Valve Regurgitation</title>
        <description>Number of participants with Moderate to severe AV valve regurgitation.</description>
        <time_frame>just before the pre-Glenn surgery</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate to Severe AV Valve Regurgitation</title>
          <description>Number of participants with Moderate to severe AV valve regurgitation.</description>
          <population>ITT, no imputation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Moderate to Severe AV Valve Regurgitation</title>
        <description>Number of participants with moderate to severe AV valve regurgitation.</description>
        <time_frame>at age 14 months</time_frame>
        <population>ITT, no imputation</population>
        <group_list>
          <group group_id="O1">
            <title>Enalapril</title>
            <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Moderate to Severe AV Valve Regurgitation</title>
          <description>Number of participants with moderate to severe AV valve regurgitation.</description>
          <population>ITT, no imputation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="93"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to 14 months of age</time_frame>
      <desc>All serious AE counts by body system are presented. The total count of affected by SAE is based on all reported SAEs.
All other AE counts by body system are presented. The total count of affected by &quot;other AE&quot; is based on all reported AEs other than serious.</desc>
      <group_list>
        <group group_id="E1">
          <title>Enalapril</title>
          <description>ACE (Angiotensin-converting enzyme) inhibitor enalapril, initial dose 0.1 mg/kg/day; Uptitrated as tolerated to target dose of 0.4 mg/kg/day given in two divided doses</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo suspension</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood/bone marrow</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>coagulation</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>hemorrhage/bleeding</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>lymphatics</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac general</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="37" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>cardiac arrhythmia</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>death</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>syndromes</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>auditory/ear</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>constitutional symptoms</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="55" subjects_affected="36" subjects_at_risk="115"/>
                <counts group_id="E2" events="44" subjects_affected="35" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>growth and development</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>metabolic/laboratory</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal/soft issue</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal/genitourinary</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/Upper Respiratory</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="115"/>
                <counts group_id="E2" events="49" subjects_affected="35" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatology/skin</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>surgery/intra-operative injury</sub_title>
                <description>Adjudication by independent medical monitor for all serious adverse events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>blood/bone marrow</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>hemorrhage/bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E2" events="15" subjects_affected="12" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>auditory/ear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>endocrine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>constitutional symptoms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatobillary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>allergy/immunology</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="66" subjects_affected="38" subjects_at_risk="115"/>
                <counts group_id="E2" events="64" subjects_affected="33" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>metabolic/laboratory</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>growth and development</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal/soft tissue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurology</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal/genitourinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/upper respiratory</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dermatology/skin</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>surgery/intra-operative injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lynn Sleeper</name_or_title>
      <organization>New England Research Institute</organization>
      <phone>617-972-3235</phone>
      <email>lsleeper@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

